Literature DB >> 11040353

Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure.

Z H Huang1, T Murakami, A Okochi, R Yumoto, J Nagai, M Takano.   

Abstract

The effect of glycerol-induced acute renal failure on P-glycoprotein expression and function was evaluated in rats. The in vivo function of P-glycoprotein was evaluated by measuring renal secretory and biliary clearance and brain distribution of rhodamine 123 (Rho-123), a P-glycoprotein substrate, under a steady-state plasma concentration. In acute renal failure rats, the P-glycoprotein level increased 2.5-fold in the kidney, but not in the liver and brain. In contrast, P-glycoprotein function in these tissues was suppressed. Interestingly, not only the renal but also the biliary clearance of Rho-123 was correlated with the glomerular filtration rate. In Caco-2 cells, plasma from renal failure rats exhibited a greater inhibitory effect on P-glycoprotein-mediated transport of Rho-123 than did plasma from control rats. In conclusion, P-glycoprotein function was systemically suppressed in acute renal failure, even though the level of P-glycoprotein remained unchanged or rather increased. This may be due to the accumulation of some endogenous P-glycoprotein substrates/modulators in the plasma in disease states.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11040353     DOI: 10.1016/s0014-2999(00)00699-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

Authors:  Kyra J Barnes; Andrew Rowland; Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2014-06-24       Impact factor: 2.953

Review 3.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

4.  Shiga-like toxin II derived from Escherichia coli O157:H7 modifies renal handling of levofloxacin in rats.

Authors:  Ying Lan Zhao; Xiao Bo Cen; Masafumi Ito; Keiko Yokoyama; Kenji Takagi; Kiyoyuki Kitaichi; Masayuki Nadai; Michio Ohta; Kenzo Takagi; Takaaki Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

5.  Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.

Authors:  H Sun; L A Frassetto; Y Huang; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  2010-01-20       Impact factor: 6.875

Review 6.  The effect of chronic renal failure on drug metabolism and transport.

Authors:  Albert W Dreisbach; Juan J L Lertora
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-08       Impact factor: 4.481

7.  Differential effect of acute hepatic failure on in vivo and in vitro P-glycoprotein functions in the intestine.

Authors:  Ryoko Yumoto; Teruo Murakami; Mikihisa Takano
Journal:  Pharm Res       Date:  2003-05       Impact factor: 4.200

8.  Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.

Authors:  Dirk R J Kuypers; Kathleen Claes; Pieter Evenepoel; Bart Maes; Willy Coosemans; Jacques Pirenne; Yves Vanrenterghem
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.

Authors:  Hiroaki Yamaguchi; Ikuko Yano; Hideyuki Saito; Ken-ichi Inui
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

10.  Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations.

Authors:  Henricus A M Mutsaers; Lambertus P van den Heuvel; Lauke H J Ringens; Anita C A Dankers; Frans G M Russel; Jack F M Wetzels; Joost G Hoenderop; Rosalinde Masereeuw
Journal:  PLoS One       Date:  2011-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.